Veracyte

Veracyte, Inc. is a global diagnostics company based in South San Francisco, California, with additional operations in Austin, Texas. Founded in 2006 as Calderome, Inc. and rebranded in 2008, Veracyte focuses on providing genomic insights to enhance cancer diagnosis, prognostication, and treatment decisions. The company employs over 900 people and is committed to transforming cancer care through advanced diagnostic tools that utilize genomic technology and machine learning. Veracyte offers a range of genomic diagnostics for various cancers, including thyroid, lung, and breast cancer. Their key products include the Afirma Gene Expression Classifier (GEC) and Genomic Sequencing Classifier (GSC) for thyroid nodules, the Percepta classifier for lung cancer risk assessment, and the Prosigna tool for breast cancer prognostics. These validated classifiers help clinicians make informed decisions and improve patient outcomes by providing actionable insights while minimizing unnecessary procedures.